



First Chinese and further European patent for GILUPI were granted in 2016

GILUPI detection device for *in vivo* and/or *in vitro* enrichment of sample

GILUPI GmbH announced today, that the company received the first Chinese and another European patent protecting the unique and innovative GILUPI technology.

The Chinese patent (ZL201080027208.2) as well as the European patent (EP2442726 B1) titles "detection device for *in vivo* and/or *in vitro* enrichment of sample material" describes a functionalized structured medical wire for the accumulation of sample material. The device comprising a biocompatible polymer and a functional surface equipped with detection receptors which for example enables the isolation of cells directly from the blood of patients (*in vivo*). This patented technology is already being used in clinical settings on national and international level.

The recently received patents are an important supplementation of GILUPI's intellectual property portfolio. Thus, the company has a broad and strong intellectual property position required to run the GILUPI businesses. GILUPI has filed further patent applications that are currently subject to examination procedures for a number of inventions, hence further granted patents will follow soon.

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector[®] enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.

The GILUPI CellCollector[®] is the first *in vivo* CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com

Press contact

GILUPI GmbH
Claudia Chudak, PhD
Hermannswerder 20 a
Tel. +49 331 58184782
Fax +49 331 58184780
E-Mail: info@gilupi.com